Microsoft word - diphenhydramine.doc

MATERIAL SAFETY DATA SHEET

Product Name: Diphenhydramine Hydrochloride Injection, USP
1. CHEMICAL PRODUCT AND COMPANY INFORMATION
Manufacturer Name
And Address
Emergency Telephone
Hospira, Inc.

Product Name

Synonyms
2. COMPOSITION/INFORMATION ON INGREDIENTS
Ingredient Name Diphenhydramine
Chemical Formula
Approximate Percent
Component
CAS Number
RTECS Number
by Weight

3. HAZARD INFORMATION
Emergency Overview
Diphenhydramine hydrochloride is an antihistamine used for relief of symptoms associated with allergies or colds, and for the treatment of symptoms associated with motion sickness. Toxic by ingestion. May cause nervous system effects.
Occupational Exposure
Information from occupational exposure is not available.
Signs and Symptoms
The most frequently observed side effects include sedation, sleepiness, breathing difficulty, disturbed coordination, hypotension, gastrointestinal upset and thickened bronchial secretions.
Medical Conditions
Clinical experience suggests narrow-angle glaucoma, peptic ulcers and other Aggravated by Exposure
gastrointestinal disorders, bladder obstruction, prostatic hypertrophy, asthma, hyperthyroid, cardiovascular disease, hypertension and concurrent use of central nervous system depressants or monoamine oxidase inhibitor therapy. 4. FIRST AID MEASURES
Eye Contact:
Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary. Product Name: Diphenhydramine Hydrochloride Injection, USP
Skin Contact:
Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Inhalation:
Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.
Ingestion:
Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.
5. FIRE FIGHTING MEASURES
Flammability: Non-flammable
Fire & Explosion

Extinguishing Media:
Use extinguishing media appropriate for primary cause of fire.
Special Fire Fighting
No special provisions required beyond normal fire fighting equipment such Procedures
as flame and chemical resistant clothing and self contained breathing apparatus.
6. ACCIDENTAL RELEASE MEASURES
Spill Cleanup and Disposal
Absorb with suitable material and dispose of materials according to applicable federal, state, or local regulations.
7. HANDLING AND STORAGE
Handling
No special storage required for hazard control. For product protection store at
Special Precautions
8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Exposure Guidelines
Exposure limits
Component OSHA-PEL
ACGIH-TLV
Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value. EEL: Employee Exposure Limit. STEL: 15-minute Short Term Exposure Limit.
Respiratory Protection
Respiratory protection is not needed during normal product use.
Skin Protection
If contact with unprotected skin is likely, glove use is prudent practice. Product Name: Diphenhydramine Hydrochloride Injection, USP

Eye Protection
Eye protection is not required during expected product use conditions but may be warranted if eye contact is likely.
Engineering Controls
Engineering controls are not needed during normal product use conditions.
9. PHYSICAL/CHEMICAL PROPERTIES
Appearance/Physical
State
Odor
Boiling Point
Approximately that of water (100o C, 212o F) Freezing Point
Vapor Pressure
Approximately that of water (17.5 mm Hg at 20o C) Vapor Density (Air=1)
Evaporation Rate Not
Bulk Density
Density 1.005
Solubility

10. STABILITY AND REACTIVITY
Chemical Stability
Stable under standard use and storage conditions.
Incompatibilities

Hazardous
Decomposition
Products

Hazardous
Polymerization
11. TOXICOLOGICAL INFORMATION:
Acute Toxicity – Oral:

Ingredient(s) Percent
Type Value
LD50 is the dosage producing 50% mortality.
Product contains approximately 5% Diphenhydramine.
Mutagenicity Not

Reproductive Effects

Target Organ Effects
Possible target organs include skin, eyes, and the central nervous, gastrointestinal, and cardiovascular systems. In animal studies, there is limited evidence of fetotoxicity and possible cleft palate formation.
12. ECOLOGICAL INFORMATION:
Aquatic Toxicity
Product Name: Diphenhydramine Hydrochloride Injection, USP
13. DISPOSAL CONSIDERATIONS:
Waste Disposal
Disposal should be performed in accordance with the federal, state or local regulatory requirements.
Container Handling
Dispose of container and unused contents in accordance with federal, state, and Disposal

14. TRANSPORTATION INFORMATION
DOT
DOT - US Department of Transportation Regulations
15. REGULATORY INFORMATION
TSCA Status
CERCLA Status
SARA Status
RCRA Status
PROP 65 (Calif.) Not
TSCA Toxic Substance Control Act CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act SARA Superfund Amendments and Reauthorization Act RCRA US EPA, Resource Conservation and Recovery Act Prop 65, California Proposition 65
16. OTHER INFORMATION:

MSDS Coordinator

Disclaimer:
The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira
does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A
WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE
MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE.
Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results
obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No
warranty against infringement of any patent, copyright or trademark is made or implied.

Source: http://thetps.com/blog/wp-content/uploads/2010/12/Diphenhydramine.pdf